MHRA approves 2 POM to P progestogen-only contraceptive pill switches

Desogestrel contraceptive pills Lovima and Hana will both be available from pharmacies from the end of July, after the MHRA approved their reclassification from POMs to P meds.

Contra%20comp%201.jpg
People will be able to obtain these contraceptive pills following a consultation with a pharmacist

The Medicines and Healthcare products Regulatory Agency (MHRA) authorised the switch of both medicines today (July 8), following a three-week consultation it ran at the beginning of the year.

Following their reclassification, people will be able to purchase Lovima and Hana 75 microgram film-coated tablets without a prescription for the first time in the UK, after a consultation with a pharmacist.

"Around £10" for 28 pills

Lovima — a daily progestogen-only pill manufactured by Maxwellia — will retail at “around £10 per month” and will be available in packs of 28 and 84 pills, Maxwellia said.

HRA Pharma’s Hana will retail at £9.95 for a one-month pack (28 pills) and £21.95 for its three-month version (84 pills).

Maxwellia deemed the switch a “momentous” step that will “enable pharmacists to broaden their frontline role” in assisting patients with more sexual health services.

Founder and CEO Anna Maxwell said the “decision has allowed us to liberate this pill for thousands of [people]”.

While HRA Pharma said: “This milestone moment will make it more convenient for [people] to access and use regular oral contraception, as they won’t need to book a GP appointment. It also recognises the growing role pharmacy has in the provision of contraception.”

Pharmacy teams will be supported with “comprehensive” training and education materials ahead of the pills’ launch, both companies said.

Stakeholders support, but C+D readers split

At the time of the consultation, the Company Chemists' Association (CCA) Professional Practice Group – which responded on behalf of the large multiples and supermarket pharmacies – told C+D it was supportive of plans to make more sexual health services available through community pharmacy.

In a poll published in March, C+D readers were split as to whether Lovima and Hana should switch from prescription-only medicine (POM) to a pharmacy (P) medicine.

What makes a successful POM to P change? Listen to the podcast below with Anna Maxwell, CEO of Maxwellia, to find out.

Follow C+D’s podcasts by searching “Chemist+Druggist podcast” on your preferred app or on Soundcloud.

Sign in or register for free

Latest from News

Revealed: Which areas have lost the most pharmacies?

 
• By 
 • comment1

New data analysis has revealed the locations of English and Welsh “pharmacy deserts” – the areas worst hit by the more than a thousand pharmacy closures over the last decade.

PSNI hikes fees 20% after flunking record number of standards

 
• By 
 • comment0

The Northern Irish pharmacy regulator has confirmed plans to increase annual fees to £477, weeks after the Professional Standards Authority (PSA) “identified weaknesses in multiple [of its] regulatory functions”.

Newspaper rapped over article promoting Mounjaro

 
• By 
 • comment0

The medicines regulator has upheld a complaint that an article naming UK sources of weight loss drug supply breached advertising regulations banning the promotion of POMs to the public.

More from Clinical

RSV jab pilot to expand by ‘up to’ 200 pharmacies

 
• By 
 • comment0

The DH has revealed plans to expand the pharmacy RSV vaccine programme by “up to 200 sites in identified target areas” in 2025/26 to “reverse the downward trend” in uptake.

Patient secures ‘urgent’ leukaemia treatment after Pharmacy First consultation

 
• By 
 • comment1

A pharmacist has been hailed as “incredible” after she spotted a patient’s leukaemia red flags during an NHS Pharmacy First Plus consultation.